The study suggested that a) Reported risk of procoagulant or thromboembolic changes in pill users is lower in low BMI &normal BMI and b) Low BMI users showed significantly longer prothrombin time due to the effect of malnutrition itself or due to the effect of pills in this nutritional background.
Effect of Low Dose Oral Contraceptive Pill on
A number of side effects were encountered by the users. These included nausea, vomiting, dizziness, metabolic disorders such as hypertention, diabetes and thromboembolic manifestations in the form of pulmonary embolism, leg vein thrombosis, coronary thrombosis and thus the estrogen component of the OCP was initially implicatedin the pill-induced thromboembolic side effects 1, 2 . But later it was shown that the gestagen componenttoo played a vital role in enhancing cardiovascular side effects 3, 4 . The introduction of low dose OCP with 30µg estrogens was a step in the right direction but further reduction resulted in breakthrough bleeding 5 .
The Dunlop committee for the safety of drugs in UK issued a declaration linking the estrogenic component
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of the pill with the risk of venous thrombosis. Consequently the doses of estrogen in the pill were reduced again and again until affecting contraceptive efficacy. As a result, the risks which were attributed to high estrogen content such as venous thrombosis, hypertension, diabetes etc were reduced. This was confirmed by the Royal College of general practitioners and the Walnat Creek Contraceptive drug study 6 .
However, such low doses was possible primarily because highly effective and more specific progestogen such as levonorgestrel, desogestrel, gestadene, norgestimateetc were developed and introduced. The development of Levonorgestrel and third generation progestogens were potentially responsible for reducing severe cardiovascular side effects 7 .
Several retrospective and prospective studies have suggested the existence of an increased risk of cardiovascular diseases, in particular venous thromboembolism, pulmonary embolism, myocardial infarction (MI) and hemorrhagic stroke in users of OCP a risk possibly related to the dose of estrogen 8, 9, 10 . It has been suggested that adhesiveness of blood platelets to a glass surface was greater in women than in man in the presence of a histone like substance derived from human brain, the adhesiveness of platelets were increased in woman because of OCP therapy 11 .
A comparisonof Japanese and American women using OCP, concluded that the effect on the fibrinolytic system were considerably better among the Japanese women than among the Americans, indicating a decreased risk of cerebral thrombosis in Japanese women 12 .
Antithrombin III (AT III) activity fell significantly during OCP useand the estrogen component was blamed for the fall 13, 14 . Low serum ATIII activity was observed in patients with pulmonary embolism,MI and venous thrombosis. The use of low estrogen pill resulted in a significant reduction in the number of thromboembolic episodes and the reduction was found to be limited in venous thromboembolism 15 .
Effect of OCP on Caucasian woman was studied and observed acceleration of the procoagulants in extrinsic and intrinsic clotting systems and reduction of the plasma AT III levels, indicating some imbalance of the hemostatic mechanism towards hypercoagulability. These changes increased with the duration of therapy and took some months to resolve when OCP were withdrawn. OCP should be avoided by woman with established cardiovascular disease or with cardiovascular risk factors, irrespective of age 16 .They further suggested that OCP appear to unsuitable method of contraception even for healthy and nonsmoker women over 40 years of age.
A large number of Bangladeshi women of various socioeconomic status are using low dose OCP. There are different types of combined low dose OCP used by the Bangladeshi women eg: Shukhi (R) , Femicon (R) , Nordette-28 (R) and Marvelon (R) .All these OCPs contain 30µg of ethinyl estradiol, but their progestogen component varies.
Shukhi is mostly used by the women of low socioeconomic status, because the family planning program of the government of Bangladesh has made it available to them free of cost. Studiesshows that newer combined low dose OCPs cause less upset in metabolic and coagulation parameters as it contains 30µg of ethinyl estradiol (EE) 17, 18 . But these need to be confirmed in Bangladeshi population with low BMI as it is well known that diet and life style can affect pill induced changes in hepatic protein synthesis.Safety of OCP has not been studied in low BMI undernourished Bangladeshi women.Due to protein deficiencies in these low BMI groups there may be different biological response in these women resulting in different risk profile.
Materials and Method:
The study was conducted at 3. There is significant difference in prothrombin time between the two groups (p=0.019), and significantly prolonged prothrombin time was noted among the Low BMI pill users ( Table-III) 4.Antithrombin III activity of the study subjects.There was no statistically significant difference found in plasma antithrombin III activity between Normal and Low BMI groups (p=0.421), showed in table-IV.The AT III activity has found to gone up towards the upper limit in both groups of pill users (normal value 88-111%).
5.Pearson correlation coefficient between BMI and coagulationstatus and ATIII. A significantly towards positive correlation was found among AT III and Low BMI(r=0.591,p=0.072)No significant correlation was found among others with BMI 6. A positive correlation was found between fibrinogen and antithrombin III in normal BMI, which is not maintained in Low BMI 
Discussion:
Subtle but complex changes occur in coagulation mechanism in women on OCP. Oral contraceptives have been shown to induce more rapid platelet aggregation and adhesion and also to reduce the activity of the fibrinolytic system, which normally breaks down the blood clot. Thus, when clot forms, they may be less likely to dissolve and more likely to reach a size sufficient to block vessels and create a thromboembolic problem. The increased risk of venous thrombosis and pulmonary embolism is probably attributable in some women to the estrogencontent of their oral contraceptives.A positive correlation was found by Inman et al in United Kingdom between the risk of thromboembolic disease and the dosage of estrogen contained in OCP, when combined OCP containing high doses (75-100 ìg or more) of estrogen, were available at that time were used 19 . The availability of new generation monophagic and multiphagic formulations of OCP containing both low dose of estrogen and new progestogen has virtually changed the previous idea of thrombogenic effect of OCP 20, 21 .
The general belief is that OCP intake leads to a high index of suspicion of thromboembolic episodes of pill users.There is limited data available regarding thrombogenic potential of OCP among Bangladeshi users. In this study, the effects of OCP on certain parameters were measured.To see the coagulation status platelet aggregation, plasma fibrinogen, prothrombin time and antithrombin III activity were measured. There was no significant change in platelet aggregation, plasma fibrinogen and antithrombin III activity in the two groups of OCP users. The prothrombin time in low BMI users was slightly prolonged by 1.6 second in contrast to normal BMI (Table III) , which was statistically significant.There may be deficiency in ionized calcium in low BMI OCP users as the study sample are from poor socioeconomic status.The plasma fibrinogen in normal BMI subject has gone up above the upper range as compared to low BMI subject (450mg/dl Vs 318 mg/ dl in Normal BMI Vs Low BMI) but the difference is not significant (p=0.332) . In this study ATIII activity in both groups were gone at the upper limit eg: in normal BMI it is 108% and in low BMI 105% (normal range : 88-111%). It is well known that OCP increases the plasma fibrinogen level. Plasma fibrinogen and AT III activity in Normal BMI subjects has gone above the upper range (450mg/dl and 108% in Plasma fibrinogen and ATIII). A positive correlation found between plasma fibrinogen and AT III in the normal BMI OCP users (r=0.355,p=0.059).We can say from the above relationship between plasma fibrinogen and AT IIIthat the rise of plasma fibrinogen is due to pill use and rise in ATIII is a secondary response to plasma fibrinogen to counterbalance the coagulation activity. It may be assumed that after a certain level of BMI increment the plasma fibrinogen will be so high at which the ATIII will not be able to counterbalance with prolong use of OCP.There was no correlation exists between the plasma fibrinogen and AT III of Low BMI OCP users.There is no significant difference in platelet aggregation in normal BMI and low BMI groups. David et al revealed in their study that the platelet count, platelet aggregation ratio were not significantly altered and antithrombin III activity was not reduced among the users of low dose oral contraceptives 20 .
Sinceprolonged prothrombin time was found within low BMI OCP users and a positive correlation existed between AT III and low BMI subjects. Reasons for such findings may be nutritional or OCP in this nutritional background. So a large extensive and indepth further study with prothrombin time, AT III, serum calcium, total plasma protein and serum albumin are also required to clarify this issue in nutritionally deprived low BMI OCP users.
Finally, the less number of low BMI subject is a limitation of this study. Initially it was thought that number of low Plasma anti-thrombin III of the subjects having normal BMI BMI women of child bearing age using OCP will be widely prevalent. During data collection it was found that low BMI women in this age group are not so common as compare to normal BMI. Cause may be gaining of weight and less linear height in this nutritional group. Reasons for gaining of weight of these women might be child bearing ,increasing age or OCP itself. On the otherhand, average height of Bangladeshi women are low in comparison to nutritionally privileged women possibly this is how the normal range of BMI is maintained in women with low socioeconomic background and also the BMI parameter in developing country is different from that of developed country.
Conclusion:
From the statistical analysis of the results obtained in present study and their comparison data suggested the following:
Low dose OCP do not seem to affect the coagulation status of Low BMI Subjects. The reported risks ofprocoagulant or thrombogenic changes in pill usersseem to be dependent on obesity, in the lower weight playing a protective role. Precautions, however, is necessary for possible bleeding disorders in low BMI users who showsignificantly longer prothrombin time due to the effect of malnutrition itself or due to the effect of pills in this nutritional background. Further studies are also required to clarify this issue of prothrombin time. AT III levels are not probably affected in underweight OCP users.It probably changes proportionately with serum fibrinogen in Normal BMISubjects. But this relationship can not be maintained in Low BMI Subjects.
